Levels of fibroblastic growth factor 23 (FGF23) in preterm newborns with subclinical phosphate deficiency

  1. Carmen Luz Marrero Pérez 1
  2. Naira Álvarez Martín 1
  3. Ruymám Miranda Morales 1
  4. Lorenzo Martín Fumero 1
  5. Carmen Vázquez Moncholí 1
  6. Víctor Manuel García Nieto 2
  1. 1 Hospital Universitario Nuestra Señora de Candelaria
    info

    Hospital Universitario Nuestra Señora de Candelaria

    Santa Cruz de Tenerife, España

    ROR https://ror.org/005a3p084

  2. 2 Universidad de La Laguna
    info

    Universidad de La Laguna

    San Cristobal de La Laguna, España

    ROR https://ror.org/01r9z8p25

Journal:
Canarias Pediátrica

ISSN: 1131-6128

Year of publication: 2016

Volume: 40

Issue: 1

Pages: 23-30

Type: Article

Abstract

Objective. To study the calciumphosphorus metabolism and both levels of fibroblast growth factor 23 (FGF23) and intact PTH in preterm newborns with subclinical phosphate deficiency. Patients and methods. A prospective study that included 29 preterm newborns (13 males, 16 females) with a gestational age of between 29 and 36 weeks during the growth phase. We studied several biochemical parameters related to calciumphosphorus metabolism and their levels in diet. Results. Preterm newborns with phosphate deficiency (n=8), also showed hypophosphaturia and hypercalciuria, with a lower growth velocity and reduced levels of both intact PTH and FGF23 related to the control group (n=21). No relation was found between the phosphate content in their diet and the existence of a deficiency of this ion in the body. Only those children who had that deficiency received a lower intake of vitamin D, although the difference was not statistically significant. Conclusions. Newborns with subclinical phosphate deficiency have reduced levels of both phosphaturic hormones in an attempt to preserve the corporal homeostasis of the ion.